Germana Tognon

3.4k total citations
38 papers, 1.2k citations indexed

About

Germana Tognon is a scholar working on Reproductive Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Germana Tognon has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Reproductive Medicine, 15 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Germana Tognon's work include Ovarian cancer diagnosis and treatment (24 papers), Endometrial and Cervical Cancer Treatments (9 papers) and PARP inhibition in cancer therapy (8 papers). Germana Tognon is often cited by papers focused on Ovarian cancer diagnosis and treatment (24 papers), Endometrial and Cervical Cancer Treatments (9 papers) and PARP inhibition in cancer therapy (8 papers). Germana Tognon collaborates with scholars based in Italy, United States and Spain. Germana Tognon's co-authors include Chiara Romani, Sërgio Pecorelli, Elisabetta Bandiera, Eliana Bignotti, Laura Zanotti, Antonella Ravaggi, Renata Tassi, Franco Odicino, Alessandro D. Santin and Enrico Sartori and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Germana Tognon

38 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Germana Tognon Italy	18	740	594	333	264	183	38	1.2k
Alexandra Sebastianelli Canada	21	508 0.7×	635 1.1×	178 0.5×	333 1.3×	135 0.7×	42	1.1k
Els Van Nieuwenhuysen Belgium	20	630 0.9×	227 0.4×	559 1.7×	372 1.4×	128 0.7×	99	1.3k
Thaïs Baert Belgium	16	558 0.8×	219 0.4×	400 1.2×	149 0.6×	189 1.0×	47	955
Fumio Kataoka Japan	16	312 0.4×	255 0.4×	248 0.7×	268 1.0×	69 0.4×	54	814
Karen A. Cadoo United States	19	247 0.3×	214 0.4×	365 1.1×	241 0.9×	75 0.4×	74	868
Alla Lisyanskaya Russia	15	550 0.7×	139 0.2×	447 1.3×	233 0.9×	303 1.7×	49	1.1k
Deanna Teoh United States	12	400 0.5×	193 0.3×	173 0.5×	253 1.0×	120 0.7×	20	708
J. Herod United Kingdom	10	275 0.4×	271 0.5×	385 1.2×	274 1.0×	182 1.0×	25	920
Yuri Matsumoto Japan	22	245 0.3×	369 0.6×	675 2.0×	324 1.2×	187 1.0×	53	1.3k
Jianqing Zhu China	16	294 0.4×	119 0.2×	318 1.0×	206 0.8×	177 1.0×	91	746

Countries citing papers authored by Germana Tognon

Since Specialization

Citations

This map shows the geographic impact of Germana Tognon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Germana Tognon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Germana Tognon more than expected).

Fields of papers citing papers by Germana Tognon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Germana Tognon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Germana Tognon. The network helps show where Germana Tognon may publish in the future.

Co-authorship network of co-authors of Germana Tognon

This figure shows the co-authorship network connecting the top 25 collaborators of Germana Tognon. A scholar is included among the top collaborators of Germana Tognon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Germana Tognon. Germana Tognon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aghajanian, Carol, Barbara Schmalfeldt, Aikou Okamoto, et al.. (2024). 751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial. Annals of Oncology. 35. S570–S571. 1 indexed citations

Christinat, Yann, Liza Ho, Sophie Clément, et al.. (2023). Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma. JCO Precision Oncology. 7(7). e2200555–e2200555. 12 indexed citations

Scambia, Giovanni, Francesco Raspagliesi, Giorgio Valabrega, et al.. (2022). Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).. Journal of Clinical Oncology. 40(17_suppl). LBA5504–LBA5504. 4 indexed citations

Romani, Chiara, Casper Reijnen, Silvia Lonardi, et al.. (2022). L1CAM expression as a predictor of platinum response in high‐risk endometrial carcinoma. International Journal of Cancer. 151(4). 637–648. 8 indexed citations

Todeschini, Paola, Elisa Salviato, Chiara Romani, et al.. (2021). Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers. 13(13). 3358–3358. 16 indexed citations

Ardighieri, Laura, Francesco Missale, Mattia Bugatti, et al.. (2021). Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. Frontiers in Immunology. 12. 690201–690201. 42 indexed citations

Colombo, Nicoletta, Angiolo Gadducci, Jalid Sehouli, et al.. (2020). LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. Annals of Oncology. 31. S1161–S1161. 16 indexed citations

Calura, Enrica, Lara Paracchini, Paolo Martini, et al.. (2019). Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study. Cells. 8(12). 1554–1554. 9 indexed citations

Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2019). Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology. 152(3). 560–567. 32 indexed citations

10.

Colombo, Nicoletta, Maria Ornella Nicoletto, Pierluigi Benedetti Panici, et al.. (2019). BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC). Annals of Oncology. 30. v896–v896. 19 indexed citations

11.

Fabbro, Michel, Kathleen N. Moore, Anne Dørum, et al.. (2017). Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC). Annals of Oncology. 28. v332–v332. 7 indexed citations

12.

Tognon, Germana, Monica Ragnoli, Stefano Calza, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 7. 325–325. 18 indexed citations

13.

Bignotti, Eliana, Renata Tassi, Stefano Calza, et al.. (2013). Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal of Translational Medicine. 11(1). 162–162. 4 indexed citations

14.

Ruggeri, Giuseppina, Elisabetta Bandiera, Laura Zanotti, et al.. (2011). HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. Clinica Chimica Acta. 412(15-16). 1447–1453. 95 indexed citations

15.

Högberg, Thomas, Mauro Signorelli, Carlos Oliveira, et al.. (2010). Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – Results from two randomised studies. European Journal of Cancer. 46(13). 2422–2431. 313 indexed citations

16.

Tassi, Renata, Stefano Calza, Antonella Ravaggi, et al.. (2009). Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer. 9(1). 253–253. 16 indexed citations

17.

Bandiera, Elisabetta, Laura Zanotti, Eliana Bignotti, et al.. (2009). Human Kallikrein 5. International Journal of Gynecological Cancer. 19(6). 1015–1021. 14 indexed citations

18.

Santin, Alessandro D., Stefania Bellone, Eric R. Siegel, et al.. (2007). Overexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas. Clinical Cancer Research. 13(11). 3339–3346. 25 indexed citations

19.

Sorio, Roberto, Germana Tognon, Angela Gambino, et al.. (2004). A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma. Tumori Journal. 90(6). 556–561. 11 indexed citations

20.

Tognon, Germana, et al.. (1994). The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. International Journal of Gynecological Cancer. 4(1). 52–60. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact